3==}^%=:;?*U#>NCKO/7/G!/17I8
SYSTEM PROCESSING...
3==}^%=:;?*U#>NCKO/7/G!/17I8
SYSTEM PROCESSING...
Posted: 2025-06-24 15:39:39 UTC
This article contains some claims that remain unverified. While much of the content may be accurate, exercise care when relying on this information.
This article contains some claims that remain unverified. While much of the content may be accurate, exercise care when relying on this information.
Status
Last Updated
2025-06-24 15:40:24 UTC
Verified By
Rollup News
The FDA has granted accelerated approval to datopotamab deruxtecan (Dato-DXd) for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletion or exon 21 (L858R) substitution mutations and have progressed on prior systemic therapy.
Accelerated approval for datopotamab deruxtecan (Dato-DXd)
Treatment of EGFR-mutated non-small cell lung cancer
Targets patients who have progressed on prior systemic therapy
Patients must have progressed on prior systemic therapy
Specific EGFR exon mutations required (exon 19 deletion or exon 21 (L858R) substitution)